- |||||||||| spironolactone / Generic mfg.
Reimbursement, Journal: Trends and patterns of neurotology drug prescriptions on a nationwide insurance database. (Pubmed Central) - Oct 22, 2021 Triamterene-hydrochlorothiazide, prednisone, montelukast, amoxicillin-clavulanate, azelastine, spironolactone, and mupirocin had statistically significant increases in average number of prescriptions per physician, whereas ofloxacin and mometasone had significant decreases...This study is the first to analyze neurotologists' trends in prescribing patterns, regional prescription cost distributions, and commonly treated pathologies. This can lead to better standardization of prescribing patterns and cost in the future.
- |||||||||| rifampicin / Generic mfg.
Journal: The evaluation of five commercial bacteriophage cocktails against methicillin-resistant Staphylococcus aureus isolated from nasal swab samples. (Pubmed Central) - Oct 20, 2021 The high susceptibility rate against ciprofloxacin (88.8%) was remarkable. The overall susceptibility of MRSA strains to ENKO, INTESTI, PYO, SES, and staphylococcal bacteriophages was 67.7%, 55.5%, 53.5%, 61.6% and 44.4%, respectively. The antibiotic susceptibility rates (except erythromycin) and efficacy of bacteriophages were higher in group A. Considering that high efficacy rates were not achieved in the study and the sensitivity rates of Turkish isolates to all phages were found to be higher than those of Syrian isolates, searching for phages in the geographic regions where the pathogen is common may be helpful to obtain suitable phages for treatment.
- |||||||||| GSK3036656 / GSK, Kerydin (tavaborole) / Pfizer
Review, Journal: Inhibitors of aminoacyl-tRNA synthetases as antimycobacterial compounds: An up-to-date review. (Pubmed Central) - Oct 14, 2021 The most promising aaRS inhibitor as an antimycobacterial compound is GSK656 (compound 8), the only aaRS inhibitor in clinical trials (Phase IIa) for systemic use against tuberculosis. GSK656 is orally available and shares the oxaborole tRNA-trapping mechanism of action with antifungal tavaborole.
- |||||||||| mupirocin / Generic mfg.
Journal, HEOR: Comparative Effectiveness Study of Home-Based Interventions to Prevent CA-MRSA Infection Recurrence. (Pubmed Central) - Sep 29, 2021 During home visits; Community Health Workers/Promotoras provided hygiene instructions; a five-day supply of nasal mupirocin; chlorhexidine for body cleansing; and household disinfecting wipes (Experimental; EXP) or Usual Care Control (UC CON) pamphlets...This intervention did not reduce clinician-reported MRSA/MSSA SSTI recurrence. Taken together with other recent studies that employed more intensive decolonization protocols, it is possible that a promotora-delivered intervention instructing treatment for a longer or repetitive duration may be effective and should be examined by future studies.
- |||||||||| mupirocin / Generic mfg., tetracycline / Generic mfg.
Clinical, Journal: Genomic Investigation of Methicillin-Resistant Staphylococcus aureus ST113 Strains Isolated from Tertiary Care Hospitals in Pakistan. (Pubmed Central) - Sep 29, 2021 The phylogenetic relationship of P10 and R46 with other prevailing MRSA strains suggests that ST113 strains are closely related to ST8 strains and ST113 strains are a single-locus variant of ST8. These findings provide important information concerning the emerging MRSA clone ST113 in Pakistan and the sequenced strains can be used as reference strains for the comparative genomic analysis of other MRSA strains in Pakistan and ST113 strains globally.
- |||||||||| Trial completion date, Trial primary completion date: STaph Aureus Resistance-Treat Early and Repeat (STAR-TER) (clinicaltrials.gov) - Sep 29, 2021
P2, N=42, Recruiting, These findings provide important information concerning the emerging MRSA clone ST113 in Pakistan and the sequenced strains can be used as reference strains for the comparative genomic analysis of other MRSA strains in Pakistan and ST113 strains globally. Trial completion date: Jun 2022 --> Jun 2023 | Trial primary completion date: Jun 2022 --> Dec 2022
- |||||||||| mupirocin / Generic mfg.
Trial completion date, Trial suspension, Trial primary completion date, Surgery: Infection Prevention Bundle in Brain Tumor Surgery (clinicaltrials.gov) - Aug 18, 2021 P=N/A, N=300, Suspended, These results suggest that a higher dose of ebselen, or a longer course of treatment, may be needed to achieve a similar effect as mupirocin in topically treating MRSA-infected pressure ulcers. Trial completion date: Feb 2022 --> Jun 2022 | Recruiting --> Suspended | Trial primary completion date: Feb 2021 --> Feb 2022
- |||||||||| mupirocin / Generic mfg.
Journal: Human organoid biofilm model for assessing antibiofilm activity of novel agents. (Pubmed Central) - Aug 18, 2021 The model was extended to evaluate thermally wounded skin infected with MRSA biofilms resulting in increased bacterial load, cytotoxicity, and pro-inflammatory cytokine levels that were all reduced upon treatment with DJK-5. Combination treatment of DJK-5 with an anti-inflammatory peptide, 1002, further reduced cytotoxicity and skin inflammation.
- |||||||||| mupirocin / Generic mfg.
[VIRTUAL] Magnetite-buforin II nanobioconjugates as active components of novel antimicrobial topical treatment (Room: Zoom Room 31) - Aug 13, 2021 - Abstract #ACSFall2021ACS_Fall_6731; The lack of highly effective antibiotics and treatments, and the growing of bacterial resistance to existing topical treatments based on mupirocin and fusidic acid, have led to the search for novel therapies based on more potent antimicrobial agents such as the antimicrobial peptides (AMPs)...Furthermore, the treatment reduced the bacterial growth of S. aureus and E. coli completely. These results are important in the context of proposing new alternatives that allow treating effectively the threat posed by the antibiotic-resistant bacterial strains, which put in serious danger the lives of thousands of people every year.
- |||||||||| Altabax (retapamulin) / GSK, Almirall, Xepi (ozenoxacin) / Maruho, Cipher, Ferrer International
Clinical, Review, Journal: A comparative review of current topical antibiotics for impetigo. (Pubmed Central) - Jul 17, 2021 Retapamulin is indicated for lesions of impetigo that are colonized by MSSA and streptococcus S. pyogenes but not MRSA based on clinical efficacy of phase III trials. Fusidic acid, available in other countries is a non-FDA approved medication although rising resistance rates represent a growing concern.
|